Population-based outcomes of patients (pt) with early-stage HER2-positive breast cancer treated with adjuvant trastuzumab (T).

被引：0
|
作者：
Noonan, Krista
McCarthy, Joy S.
机构：
[1] BC Canc Agcy, Vancouver, BC, Canada
[2] Dr H Bliss Murphy Canc Ctr, St John, NF, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11079
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer
    Haq, Bushra
    Geyer, Charles E.
    WOMENS HEALTH, 2009, 5 (02) : 135 - 147
  • [32] Duration and Toxicity of Adjuvant Trastuzumab in Older Patients With Early-Stage Breast Cancer: A Population-Based Study
    Vaz-Luis, Ines
    Keating, Nancy L.
    Lin, Nancy U.
    Lii, Huichuan
    Winer, Eric P.
    Freedman, Rachel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (09) : 927 - +
  • [33] Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment
    Genuino, Anne Julienne
    Gloria, Mac Ardy Junio
    Chaikledkaew, Usa
    Reungwetwattana, Thanyanan
    Thakkinstian, Ammarin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (05) : 1001 - 1010
  • [34] Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer
    Hajjar, Ali
    Ergun, Mehmet A.
    Alagoz, Oguzhan
    Rampurwala, Murtuza
    PLOS ONE, 2019, 14 (06):
  • [35] KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer
    Mamounas, Eleftherios P.
    Geyer, Charles E., Jr.
    Huang, Chiun-Sheng
    Mano, Max S.
    Loibl, Sibylle
    Untch, Michael
    Wolmark, Norman
    Rastogi, Priya
    Schneeweiss, Andreas
    Redondo, Andres
    Fischer, Hans H.
    Jacot, William
    Conlin, Alison K.
    Arce-Salinas, Claudia
    Wapnir, Irene L.
    Jackisch, Christian
    DiGiovanna, Michael P.
    Fasching, Peter A.
    Crown, John P.
    Wuelfing, Pia
    Shao, Zhimin
    Caremoli, Elena Rota
    Wu, Haiyan
    Lam, Lisa H.
    Tesarowski, David
    Smitt, Melanie
    Douthwaite, Hannah
    Singel, Stina M.
    von Minckwitz, Gunter
    SWISS MEDICAL WEEKLY, 2019, 149 : 13S - 13S
  • [36] Adjuvant trastuzumab and vinorelbine for early-stage HER2+breast cancer
    McLaughlin, Shannon
    Nakajima, Erika
    Bar, Yael
    Hutchinson, Jennifer A. A.
    Shin, Jennifer
    Moy, Beverly
    Isakoff, Steven J. J.
    Bardia, Aditya
    Kuter, Irene
    Spring, Laura M. M.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [37] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Kurebayashi, Junichi
    Kanomata, Naoki
    Yamashita, Tetsumasa
    Shimo, Toshiro
    Mizutoh, Akiko
    Moriya, Takuya
    Sonoo, Hiroshi
    BREAST CANCER, 2015, 22 (03) : 292 - 299
  • [38] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Junichi Kurebayashi
    Naoki Kanomata
    Tetsumasa Yamashita
    Toshiro Shimo
    Akiko Mizutoh
    Takuya Moriya
    Hiroshi Sonoo
    Breast Cancer, 2015, 22 : 292 - 299
  • [39] Trastuzumab - A review of its use in the management of HER2-positive metastatic and early-stage breast cancer
    Plosker, GL
    Keam, SJ
    DRUGS, 2006, 66 (04) : 449 - 475
  • [40] Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study
    Shao, Zhimin
    Tseng, Ling-Ming
    Huang, Chiun-Sheng
    Pang, Da
    Yang, Youngsen
    Li, Wei
    Liao, Ning
    Geng, Cuizhi
    Zhang, Qingyuan
    Xu, Binghe
    Liu, Donggeng
    Kwong, Ava
    Yu, Mandy
    Sun, Guofang
    Mobus, Volker
    Dent, Susan
    Arahmani, Amal
    Borthwick, Gillian
    Henot, Frederic
    von Minckwitz, Gunter
    Jiang, Zefei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 345 - 353
12345